What’s Happening

Date

Title


01 Jul 2024 Restalyst
Restalyst will be participating in Medica 2024 this coming November 2024.

Restalyst will be participating in Medica 2024 this coming November 2024. . Restalyst will be participating in Medica, one of the largest medical trade fair in the world for medical technology and healthcare, from 11…

20 Jun 2024 Restalyst
Restalyst received regulatory approval from DMEHW in Vietnam.

Restalyst received regulatory approval from DMEHW in Vietnam. . Restalyst 3 cancer diagnostic solutions namely, NPC-REAAD™ EBV EA-IgA ELISA, GC-REAAD™ ITIH3 ELISA, and HCC-REAAD™ ERBB3 ELISA have been approved for clinical use in Vietnam.

24 Apr 2023 Restalyst
Restalyst launched new diagnostic assays for Nasopharyngeal Carcinoma and granted Special Access Route (SAR) from Health Sciences Authority, Singapore.

Restalyst launched new diagnostic assays for Nasopharyngeal Carcinoma and granted Special Access Route (SAR) from Health Sciences Authority, Singapore. . The early detection of Nasopharyngeal carcinoma via diagnostic screening in the laboratory is essential in…

10 Jun 2022 Restalyst
Restalyst is in partnership with All India Institute of Medical Sciences (AIIMS) for a new clinical evaluation in New Delhi

This project is aimed to study the diagnostic performance of ERBB3 using Restalyst‘s HCC-REAAD™ ERBB3 ELISA together with its diagnostic algorithm for early detection of Hepatocellular Carcinoma in Southern Asia population.

23 Feb 2022 Restalyst
Restalyst had been granted Pandemic Special Access Route (PSAR) for the supply of COVID19N-REAAD™ Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA

COVID19N-REAAD™ is intended for professional use in detecting COVID-19 patients by detecting patient’s anti-SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of antibodies is…

29 Jun 2021 Restalyst
Restalyst received Singapore HSA Provisional Authorization approval for COVID19-REAAD™ Anti-SARS-CoV-2 IgG ELISA

This is a product intended for qualitative & quantitative detection of IgG antibodies to SARS-CoV-2 proteins in human serum and plasma.

01 Sep 2020 Restalyst
Restalyst signed research collaboration agreement with the National University of Malaysia

Project to investigate the use of ITIH3 biomarker in screening of individuals with gastric cancer risk

24 Aug 2020 Restalyst
PRESS RELEASE – Singapore’s Restalyst develops highly sensitive COVID-19 antibody test comparable to market leaders

Singapore biomedical firm Restalyst has developed a COVID-19 antibody test, COVID19N-REAAD™, which will be instrumental in establishing disease prevalence in populations and the exposure risk factors associated with infection. Press release was made to countries…

07 Aug 2020 Restalyst
Restalyst received Singapore HSA Provisional Authorization approval for COVID19N-REAAD™ Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA.

This is a product intended for qualitative detection of IgG antibodies to SARS-CoV-2 Nucleocapsid Protein in human serum and plasma.

01 Jul 2020 Restalyst
Restalyst received Singapore HSA Provisional Authorization approval for RAPIT COVID-19 IgM/IgG Test Kit

This a lateral flow chromatography immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in human plasma, serum, finger pricked whole blood or whole blood.

22 Nov 2019 Restalyst
Restalyst @ MEDICA 2019

18-21 Nov 2019. Restalyst participated in Medica 2019 under the Singapore Pavilion to promote her innovative cancer tests to the world.

10 Oct 2018 Restalyst
Restalyst @ MEDICA 2018

12 – 15 Nov 2018 As part of its commitment to continuous innovation, Restalyst will be participating in Medica 2018. Visit us at Singapore Pavilion Hall 3 Booth G74.

20 Aug 2018 Restalyst
Restalyst received Singapore HSA approval for an improved version of its gastric cancer screening kit – GC-REAAD™

GC-REAAD™, an in-vitro diagnostic medical device for the early detection of gastric cancer, was developed based on competitive ELISA platform in 2015. It was recently improved to a sandwich ELISA platform and approved by Singapore…

11 Nov 2016 Restalyst
Restalyst launched effective liver cancer diagnostic kit at MEDICA 2016

This ELISA-based diagnostic kit (known as HCC REAAD) was developed by Restalyst based on patented technology by the Chang Gung Memorial Hospital (Taiwan).

11 Nov 2015 Restalyst
Restalyst launched new, more accurate gastric cancer screening kit at MEDICA 2015

This ELISA-based diagnostic kit (known as GC-REAAD) was developed by Restalyst together with the National University of Singapore.